Rivastigmine Bioequivalence Trial With Multiple Applications of Transdermal Patches (9.5 mg/24 h)
Clinical trial NCT05883124 · COMPLETED
Trial details
- NCT number
- NCT05883124
- Sponsor
- SocraTec R&D GmbH
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-04-17
- Primary completion
- 2023-06-19
- Enrollment
- 38
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.